Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC - ILCN.org (ILCN/WCLC)
VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC #StudyGraphics #lungcancer | Tyrosine, Survival, Medicine
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEJM
Overall survival in patients who received osimertinib in any line... | Download Scientific Diagram
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - ScienceDirect
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
Kaplan-Meyer curves for progression free survival of osimertinib by (a)... | Download Scientific Diagram
EGFR-positive tumors: the issue of optimal therapy across several lines - memoinOncology
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
EGFR-mutant lung cancer: sequencing as a major topic in light of new data - memoinOncology
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer - Lung Cancer
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Results for two new third-generation EGFR TKIs
A) Overall survival of sequential therapy for afatinib followed by... | Download Scientific Diagram
